{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T07:27:25Z","timestamp":1774078045319,"version":"3.50.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11,1]]},"DOI":"10.1164\/rccm.201509-1881ed","type":"journal-article","created":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T14:27:42Z","timestamp":1446215262000},"page":"1032-1033","source":"Crossref","is-referenced-by-count":6,"title":["Screening and Early Detection of Pulmonary Arterial Hypertension in Connective Tissue Diseases. It Is Time to Institute It!"],"prefix":"10.1093","volume":"192","author":[{"given":"Dinesh","family":"Khanna","sequence":"first","affiliation":[{"name":"University of Michigan Scleroderma Clinic, Ann Arbor, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vallerie","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"Pulmonary Hypertension Program, University of Michigan, Ann Arbor, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,11,1]]},"reference":[{"key":"2026032100150405900_bib1","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.10-0260","article-title":"Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype","volume":"138","author":"Chung","year":"2010","journal-title":"Chest"},{"key":"2026032100150405900_bib2","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1378\/chest.12-0653","article-title":"Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era","volume":"144","author":"Rubenfire","year":"2013","journal-title":"Chest"},{"key":"2026032100150405900_bib3","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"key":"2026032100150405900_bib4","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3899\/jrheum.100245","article-title":"Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies","volume":"37","author":"Avouac","year":"2010","journal-title":"J Rheumatol"},{"key":"2026032100150405900_bib5","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study","volume":"73","author":"Coghlan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026032100150405900_bib6","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1002\/art.38172","article-title":"Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension","volume":"65","author":"Khanna","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2026032100150405900_bib7","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1002\/art.30541","article-title":"Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival","volume":"63","author":"Humbert","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2026032100150405900_bib8","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/art.10775","article-title":"Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement","volume":"48","author":"Steen","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2026032100150405900_bib9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/acr.21827","article-title":"Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: utility of the University of California, San Diego, Shortness of Breath Questionnaire","volume":"65","author":"Chung","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026032100150405900_bib10","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1164\/rccm.201507-1456OC","article-title":"Comparison of treatment response in idiopathic and connective tissue disease\u2013associated pulmonary arterial hypertension","volume":"192","author":"Rhee","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100150405900_bib11","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"2026032100150405900_bib12","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201507-1398OC","article-title":"Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension","volume":"192","author":"Hassoun","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100150405900_bib13","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2026032100150405900_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/annrheumdis-2015-eular.2332","article-title":"Initial combination therapy of ambrisentan and tadalafil in connective tissue disease associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the ambition trial","volume":"74","author":"Coghlan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026032100150405900_bib15","first-page":"A2199","article-title":"Sel7017 selexipag prolongs the time to morbidity\/mortality events in key subgroup populations: results from GRIPHON, a randomized controlled study in pulmonary arterial hypertension [abstract]","volume":"191","author":"Chin","year":"2015","journal-title":"Am J Respir Crit Care Med"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/192\/9\/1032\/67213768\/ajrccm_192_9_1032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/192\/9\/1032\/67213768\/ajrccm_192_9_1032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:15:07Z","timestamp":1774066507000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/192\/9\/1032\/8504636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,1]]},"references-count":15,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,11,1]]},"published-print":{"date-parts":[[2015,11,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201509-1881ed","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,11]]},"published":{"date-parts":[[2015,11,1]]}}}